Blood collection

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Blood collection is one of 374 biologic programs targeting Recovery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

373

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecoveryCompleted

Kidney CancerActive, not recruiting

Colorectal CancerActive, not recruiting

MigraineActive, not recruiting

COVID-19Active, not recruiting

AsthmaActive, not recruiting

DementiaActive, not recruiting

AspergillosisActive, not recruiting

HepatitisActive, not recruiting

Pulmonary EdemaActive, not recruiting

RecoveryPreclinical

Completed

Kidney CancerPreclinical

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

DementiaPreclinical

Active, not recruiting

AspergillosisPreclinical

Active, not recruiting

HepatitisPreclinical

Active, not recruiting

Pulmonary EdemaPreclinical

Active, not recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Aimovig

Amgen

Preclinical

1 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 8

Tricor

JJagotec

Preclinical

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Antibody

NCT06373510

Q1 2028

Recruiting

Migraine

NCT07177885

Q1 2029

Recruiting

Rejection

NCT07134491

Clinical

Trials by Indication[1]

Age2 trials

Macrophages, GM-CSF and MARS Proteinosis

Completed·AAssistance Publique - Hôpitaux de Paris··NCT04811274·20 enrolled

Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Completed·RRennes University Hospital·N/A·NCT04473742·23 enrolled

Ankylosing Spondylitis1 trial

Ankylosing Spondylitis and Antiphospholipid Antibodies

Unknown status·CCHU de Reims·N/A·NCT02809300·80 enrolled

Efficacy1 trial

Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response

Completed·SSociété des Produits Nestlé (SPN)·N/A·NCT05570435·31 enrolled

Paclitaxel1 trial

Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel

Completed·CCentre Oscar Lambret·Phase 1·NCT01374620·28 enrolled

Antibody1 trial

Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study

Not yet recruiting·CCerbaXpert·N/A·NCT06373510·10,000 enrolled

16 more indications

Idiopathic Parkinson's Disease1 trial

Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions

Unknown status·—··NCT05110547·75 enrolled

Dementia1 trial

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders

Unknown status·WWoolcock Institute of Medical Research··NCT06377332·104 enrolled

Rejection1 trial

Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity

Recruiting·AAssistance Publique - Hôpitaux de Paris··NCT07134491·45 enrolled

Aspergillosis1 trial

PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02955966·51 enrolled

Recruiting·UUniversity Hospital, Clermont-Ferrand··NCT07177885·144 enrolled

Hepatitis1 trial

Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis

Completed·CCHU de Reims·N/A·NCT02808663·6 enrolled

Asthma1 trial

Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma

Withdrawn·AAssistance Publique - Hôpitaux de Paris··NCT03784781

Stress1 trial

Contribution of L-Tyrosine to Human Decision Making in Stressful Situations

Completed·DDirection Centrale du Service de Santé des Armées·N/A·NCT04518254·17 enrolled

Colorectal Cancer1 trial

Development of a Serum Test for Colorectal Cancer Screening (COLODIAG préclinique)

Completed·—··NCT04659018·30 enrolled

COVID-191 trial

Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff

Completed·DDirection Centrale du Service de Santé des Armées··NCT04408001·499 enrolled

Kidney Cancer1 trial

Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT05285579·100 enrolled

Recovery1 trial

Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation

Completed·DDirection Centrale du Service de Santé des Armées·N/A·NCT04549194·116 enrolled

Allergy in Children1 trial

Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children

Completed·AAssistance Publique - Hôpitaux de Paris··NCT03776474·135 enrolled

Unspecified2 trials

Pharmacogenetic DNA Bank

Unknown status·NNational University Hospital, Singapore··NCT00941200·5,000 enrolled

Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population

Unknown status·NNational University Hospital, Singapore··NCT01050920

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Blood collection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood collection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood collection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Blood collection

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Age2 trials

Ankylosing Spondylitis1 trial

Efficacy1 trial

Paclitaxel1 trial

Antibody1 trial

Idiopathic Parkinson's Disease1 trial

Dementia1 trial

Rejection1 trial

Aspergillosis1 trial

Antidepressants1 trial

Pulmonary Edema1 trial

Migraine1 trial

Hepatitis1 trial

Asthma1 trial

Stress1 trial

Colorectal Cancer1 trial

COVID-191 trial

Kidney Cancer1 trial

Recovery1 trial

Allergy in Children1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News